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German.18 With a cutoff of 5 points, the questionnaire has a 
sensitivity of 96% and a specifi city of 56% in subjects with 
sleep-wake disorders and of 92% in control subjects.18 A vali-
dation study of RBDSQ in 75 PD patients with a cutoff of the 
initially suggested 5 points yielded a sensitivity of 68% and 
specifi city of 63%.19 In another validation study of RBDSQ in 
PD patients, a cutoff of 6 points showed much higher sensitiv-
ity (84%) and specifi city (96%).20
In a follow-up polysomnography (PSG) study we tested 
10 PD patients with RBDSQ scores ≥ 10. All of them pre-
sented with RBD in PSG including RWA and pronounced 
behavioral peculiarities. We also tested 10 patients with 
RBDSQ scores ≤ 2. Among them, 5 patients had RWA and 
gross body jerks in PSG despite the low scores on RBDSQ 
(unpublished data).
Study Objectives: REM sleep behavior disorder (RBD) is re-
ported in up to 50% of patients with Parkinson’s disease (PD). 
Only a few systematic, large-scale studies have addressed the 
characteristics of RBD in PD. The aim of the present study is 
to assess the frequency of RBD in patients with PD and the 
association with PD characteristics.
Methods: We sent a questionnaire including items on sleep 
quality, sleep disorders, and PD characteristics and sever-
ity to the members of the national PD patients’ organization 
in Switzerland. To assess and characterize RBD, we used a 
validated 10-item questionnaire (the RBD screening question-
naire, RBDSQ).
Results: Four hundred seventeen PD patients returned the 
questionnaire, with RBD scores ≥ 6 in 172 patients. These pa-
tients had longer disease duration and lower activity of daily liv-
ing scores, as well as more frequent nighttime awakenings and 
hallucinations than PD patients with RBDSQ scores < 6. Age, 
gender, sleep-wake disorders such as excessive daytime sleepi-
ness, sleep apnea, and insomnia, as well as levodopa equivalent 
dose did not differ between the 2 groups. Patients with RBDSQ 
score ≥ 6 were more often treated with antidepressants.
Conclusions: We confi rm a frequent (42.6%) history of RBD 
in PD. Probable RBD in PD is associated with more advanced 
disease as suggested by the longer disease duration and high-
er impairment of daily living. It is also linked to sleep fragmen-
tation with signifi cantly more nighttime awakenings and with 
hallucinations. Hallucinations might be linked to emotional dis-
inhibition and probably to activation of limbic structures. Both 
sleep fragmentation and limbic activation might facilitate the 
occurrence of RBD in PD.
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R EM behavior disorder (RBD) in humans was fi rst de-scribed by Schenck et al. in 1986.1 It is characterized 
by loss of normal muscle atonia during REM sleep, which 
leads to increased phasic motor activity and allows dream 
enactment behavior.2 Most patients report vivid, frightening 
dreams, leading to violent behavior, often resulting in injuries 
of patients or their bed partners.3 The prevalence of RBD re-
ported in the general population is < 1%,4,5 whereas in neuro-
degenerative disorders, especially synucleinopathies such as 
Parkinson’s disease (PD), dementia with Lewy bodies (DLB), 
and multiple system atrophy (MSA), a much higher frequency 
is found.6,7 It has been shown that PSG is the gold standard for 
the diagnosis of RBD, since only half of the patients are de-
tected by history.8,9 RBD is reported in up to 47% of patients 
with PD, based on video-polysomnography (PSG),8 and REM 
sleep without atonia (RWA) in up to 58%.9 It has been sug-
gested that RWA might represent a preclinical form of RBD 
associated with PD.9 Until now, several large questionnaire 
and interview-based studies have addressed RBD in PD, in-
cluding numbers of 150 to 320 patients.10-14 In these studies 
the frequency varied from 27% to 54%, which is close to PSG-
based reports.10-14 As RBD may precede the motor symptoms 
of neurodegenerative disorder by years,15-17 there have been 
multiple attempts to fi nd a questionnaire-based diagnostic tool 
for RBD. Recently, the REM sleep behavior disorder screen-
ing questionnaire (RBDSQ) was developed and validated in 
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bRIEF SUMMaRY
Current Knowledge/Study Rationale: RBD is very common in PD 
and there have been multiple attempts to fi nd a questionnaire based 
diagnostic tool for RBD. For the fi rst time we use a previously validated 
questionnaire tool assessment of RBD in a large, unselected sample of 
PD patients.
Study Impact: RBD in PD could be detected by a validated question-
naire tool in 42.6% of the patients, which is comparable to the frequency 
found in PSG-based studies. It was associated with more advanced dis-
ease, sleep fragmentation and hallucinations.
56Journal of Clinical Sleep Medicine, Vol. 9, No. 1, 2013
R Poryazova, M Oberholzer, CR Baumann et al
For the first time we use a validated questionnaire tool in PD 
patients for assessment of RBD in a large, unselected sample 
of PD patients. The aim of the present study is to assess the 
frequency of RBD in patients with PD and the association with 
PD characteristics.
METHODS
We sent a questionnaire on sleep-wake disorders and PD 
characteristics to the members of the national PD patients’ or-
ganization in Switzerland. The questionnaire was attached to 
the monthly magazine of the organization. Members of the or-
ganization are not only patients with PD but also their caregiv-
ers and relatives as well as many physicians. A total of 6,000 
surveys were sent, including the French and the Italian speak-
ing parts of Switzerland but the questionnaire was provided 
only in German. We did not receive information on how many 
of the recipients are patients. Help of partners and caregivers 
was accepted but not required for completing the survey. Sleep 
habits, sleep quality, and sleep-wake disorders were assessed 
by 17 questions. The answers provide information on symp-
toms and signs suggestive of obstructive sleep apnea (OSA), 
excessive daytime sleepiness (EDS), parasomnias, hallucina-
tions, and insomnia. Possible answers include “yes” and “no” 
or provide a rating on a 5-point scale depending on the fre-
quency of occurrence (“almost always,” “often,” “occasional-
ly,” “seldom,” or “never”). As a screening question for restless 
legs symptoms, we included the single validated question as 
suggested from the International Restless Legs Syndrome 
(RLS) Study group.21,22 EDS and RBD were addressed by vali-
dated questionnaires—the Epworth Sleepiness Scale (ESS)23 
and RBDSQ. RBDSQ is a self-rating instrument, consisting 
of 10 yes-no questions. It assesses the frequency and content 
of dreams, and their relationship to nocturnal movements and 
behaviors, self-injuries and injuries of the bed-partner, noctur-
nal vocalization, sudden limb movements and complex move-
ments during sleep, nocturnal awakenings, disturbed sleep 
in general, and the presence of neurological disorders. The 
RBDSQ can be found in Table S1. Values > 6 points are con-
sidered suggestive for RBD.20 The questionnaire also assessed 
PD characteristics, with 6 items gathering information on time 
of first symptoms, diagnosis and start of treatment, invasive 
treatment, and type of the PD.
All patients were treated by a general practitioner or a neurol-
ogist for Parkinson’s disease. All patients allowed us to contact 
their physicians if confirmation of the diagnosis was needed. 
To judge the severity of PD, the Schwab and England activities 
of daily living (ADL) scale was used. The scale estimates a 
person’s ability to perform daily activities in terms of speed and 
independence through a percentage figure, with 100% indicat-
ing total independence, falling to 0%, which indicates a state of 
complete dependence.24
All patients provided a list of their medications. Levodopa 
equivalent dose (LED) was calculated for each patient.25
The study was approved by the local ethics committee, and 
all patients signed an informed consent, which was attached to 
the questionnaire.
Statistical analysis was performed using SPSS 15 software. 
Chi-square, t-tests, and Mann-Whitney tests were used to ana-
lyze categorical and continuous variables, respectively. The 
variables, which were significantly different between patients 
with and without RBD in t-tests and Mann-Whitney tests, were 
subsequently entered in a binary logistic regression analysis. 
Significance level was set at p < 0.05.
RESULTS
Four hundred seventeen patients with PD returned the ques-
tionnaire. Demographics, clinical characteristics, and treatment 
of the study population are presented in Table 1. Caregiver 
support for filling in the questionnaire was reported by 61% 
of the patients. Thirteen patients did not completely fill in the 
RBDSQ, and were excluded from further analysis. One hun-
dred seventy-two of the remaining 404 patients (42.6%) had an 
RBDSQ score ≥ 6 (suggestive of probable RBD), and 232 pa-
tients had a score < 6. Clinical and demographic characteristics 
of the 2 groups are presented in Table 2.
According to t-tests/Mann-Whitney tests a number of vari-
ables were significantly different between patients with RBDSQ 
score ≥ 6 and < 6. However when these variables were entered 
in a binary logistic regression analysis, only disease duration, 
ADL score, nighttime awakenings, and hallucinations proved 
to be significantly different between the 2 groups. RBDSQ 
scores were equally distributed in men and women. Thirty-six 
patients reported sleepwalking; 22 of them had a score ≥ 6 on 
the RBDSQ.
Three hundred ninety-six patients were treated with dopa-
minergic agents: 129 were on levodopa monotherapy, and 49 
on dopamine agonist monotherapy. Five patients received nei-
ther levodopa nor dopamine agonists; 2 patients were treat-
ed with deep brain stimulation; and 1 underwent stereotactic 
thalamothomy. Thirteen patients did not provide information 
Table 1—Demographic and clinical characteristics of the 
study population
Variable
Age, y 69 ± 9
Gender, % 68% men
ESS 10 ± 5
ESS ≥ 10, % 47
Sleep problem, % 57
Disease duration, y 11 ± 7
ADL, % 76 ± 17
Levodopa equivalent dose, mg 619 ± 424
COMT inhibitors, % 27
Amantadine, % 12
Biperiden, % 5
MAO-B inhibitors, % 12
Antidepressants, % 22
Neuroleptics, % 8
Benzodiazepines*, % 14
Dementia medication, % 3
ADL, activities of daily living (Schwab and England); COMT, Catechol-O-
methyltransferase; ESS, Epworth Sleepiness Scale; MAO-B, monoamine 
oxidase B. *Including zolpidem/zopiclone.
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on their therapy. In addition, 36 patients did not provide do-
paminergic drugs doses. One hundred sixty three patients with 
RBDSQ ≥ 6 were treated with dopaminergic agents: 54 of 
them received levodopa, and 19 received dopamine agonists 
as monotherapy. The rest of the patients were treated with a 
combination of levodopa and a dopamine agonist. Dopamine 
agonist and levodopa equivalent doses (LED), as well as ad-
ditional medications with possible influence on sleep-wake 
regulation are presented in Table 3. Levodopa and LED were 
higher in patients with history of RBD according to t-tests, yet 
after entering the data in binary logistic regression analysis, 
the results were no longer significant. Patients with RBDSQ 
≥ 6 were treated more often with antidepressants, including 
tricyclic antidepressants and SSRIs, as well as cholinesterase 
inhibitors. Only 13 patients (3 with no history of RBD) were 
treated with cholinesterase inhibitors.
DISCUSSION
We used RBDSQ, recently validated in PD patients with a 
cutoff of 6 points,20 to identify patients with probable RBD in a 
large sample of PD patients. Nearly 43% of our patients had a 
RBDSQ score ≥ 6, suggestive of RBD, which is higher than the 
frequency reported in most previous history-based studies and 
close to PSG-based studies.10-13 Probable RBD in our patient 
population was associated with nighttime awakenings, hal-
lucinations, longer disease duration, and lower ADL score. In 
disagreement with other studies, we did not find gender differ-
ences between the groups with and without suggested RBD.13,14 
Patients with suggested RBD were more often treated with anti-
depressants, including tricyclic antidepressants and SSRIs.
In comparison to previous history-based studies,11-13 our 
RBDSQ-based study revealed a higher prevalence of RBD in 
Table 2—Demographic and clinical characteristics of groups with and without probable RBD
Variable RBD score ≥ 6, n = 172 RBD score < 6, n = 232 p (t-test, χ2, Mann-Whitney test) p (binary logistic regression)
Age, y 69.5 ± 8.3 69.2 ± 9.7 NS –
Age at PD onset, y 57.5 ± 10.1 59.6 ± 10.8 NS –
Gender (males, %) 70% 66% NS –
ESS 11 ± 5.5 9.5 ± 5.1 0.006 NS
Disease duration, y 11.7 ± 7.9 9.5 ± -6.4 0.002 0.017
ADL, % 73 ± 17 77 ± 16 0.022 0.043
LED, mg 732 ± 392 648 ± 367 0.042 NS
Night-time awakenings 2.6 ± 1.3 2.2 ± 1.2 0.001 0.033
Snoring 2.8 ± 1.2 2.5 ± 1.1 0.034 NS
Apneas/hypopneas 1.9 ± 1 1.5 ± 0.8 0.003 NS
Out of breath at night 1.7 ± 0.8 1.4 ± 0.7 0.003 NS
RLS symptoms 2.5 ± 1.3 2 ± 1.2 < 0.001 NS
Visual hallucinations 2.1 ± 1.1 1.5 ± 0.9 < 0.001 0.002
ADL, activities of daily living (Schwab and England); ESS, Epworth Sleepiness Scale; LED, levodopa equivalent dose; PD, idiopathic Parkinson’s disease; 
RBD, REM sleep behavior disorder; RLS, restless legs syndrome.
Table 3—Medications in groups with and without probable RBD
Drug RBD score ≥ 6, n = 172 RBD score < 6, n = 232 p
Dopamine agonist equiv. dose, mg 214 ± 230 206 ± 251 NS
Levodopa equiv. dose, mg 732 ± 392 648 ± 367 NS
COMT inhibitors, n/% 54/31% 58/25% NS
Amantadine, n/% 25/15% 22/10% NS
MAO-B inhibitors/n, % 22/13% 26/11% NS
Biperiden, n/% 5/3% 15/7% NS
Antidepressants, n/% 54/31% 33/14% < 0.001
tricyclics, n/% 16/9% 10/4% 0.035
SSRI, n/% 24/14% 13/6% 0.004
mianserin, n/% 5/3% 1/0.4% NS
SNRI, n/% 11/6% 9/4% NS
Neuroleptics, n/% 18/10% 13/6% NS
Cholinesterase inhibitors, n/% 10/6% 3/1% 0.012
Benzodiazepines, n/% 20/12% 26/11% NS
Zolpidem/zopiclone, n/% 6/3% 5/2% NS
COMT, Catechol-O-methyltransferase; MAO-B, monoamine oxidase B; RBD, REM sleep behavior disorder; SSRI, selective serotonin reuptake inhibitors; 
SNRI, serotonin/noradrenalin reuptake inhibitors.
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PD. The combination of items on dream characteristics, noc-
turnal behaviors, and sleep disturbance may yield a higher 
sensitivity than previously used methods. In RBDSQ, not 
only violent movements are addressed, but also gestures and 
complex movements. Such complex nonviolent motor behav-
iors were recently described in RBD patients.26 Including such 
movements in the score might have increased the sensitivity of 
the questionnaire. The frequency found in our study is closer to 
polysomnographic studies8,9,27 than to most history-based stud-
ies. Sixel-Döring et al. confirmed RBD polysomnographically 
in 46% of their sleep-disturbed PD patients.27 Interestingly, a 
similar frequency of RBD was reported by Ondo et al. (43%) 
based on only one question: “acting out dreams.”10 In this study, 
however, in 27% of the patients the answer to the question was 
“not known,” which might have led to underestimation of the 
patients with suggested RBD. Similarly, an even higher fre-
quency of RBD in PD based on history (54%) was found by 
Yoritaka et al., who studied 150 patients.14
A male preponderance has been found not only in idiopathic 
RBD but also in RBD in PD patients13,14 in comparison to non-
RBD PD patients. Seventy percent of our patients with suggest-
ed RBD were male, similar to other reports.8,12,13,28 Yet no such 
gender differences have been observed in non-RBD patients.13,14 
In our study, 66% of the non-RBD patients were males; in other 
words, unlike previous reports we did not find a difference in 
the male/female ratio between the two groups. One possible ex-
planation is the known slight male preponderance of PD. This 
finding might also be explained by the assessment of nonviolent 
behaviors in RBDSQ. Gender differences in dream content and 
dream enactment behaviors have been described. Whereas men 
experience both fear and anger in their dreams and have violent 
nocturnal behaviors, women experience mainly fear and do not 
act aggressively in their dreams.29 It is possible that patients 
with nonaggressive nocturnal behaviors receive less medical at-
tention, which might lead to underestimation of RBD frequency 
in women. Similar to other studies, we did not find association 
with age13,30 or LED.12,14
As previously reported,12,27 our patients with probable RBD 
had longer disease duration and higher disease severity (as ex-
pressed by the ADL score), pointing to more advanced disease.
Tricyclic antidepressants and SSRIs are known to aggra-
vate RBD symptoms in both idiopathic and secondary cases of 
RBD.31 Our patients with probable RBD, consistent with previ-
ous reports, were treated more often with these drugs compared 
to patients with no history for RBD according to RBDSQ.
Patients with probable RBD more often reported concomi-
tant sleep disorders such as nighttime awakenings and hallu-
cinations. In agreement with a number of reports,11,13,14,32-34 we 
found a higher frequency of hallucinations in patients with 
probable RBD. This finding may have different explanations:
First, hallucinations and REM sleep disturbance may be at-
tributed to midbrain lesions, as the substantia nigra pars reticu-
lata projects to brainstem nuclei, regulating REM sleep and to 
limbic structures.35 Loss of normal muscle atonia may occur 
due to brainstem lesions, and emotional disinhibition in REM 
sleep may occur due to the activation of limbic structures.
Second, hallucinations have been linked to cognitive im-
pairment. In PD, though, patients with visual hallucinations 
may present with, but also without dementia. Harding and 
Halliday showed that both groups had LB in limbic structures, 
in particular in the basolateral nucleus of the amygdala.36 The 
main difference between the two groups was the absence of 
neocortical LB in the patients without dementia.36,37 Based 
on these findings, they suggested that visual hallucinations 
and cognitive impairment in PD are likely to have different 
underlying pathology.36
We are aware of the limitations of our study. As this was a 
postal survey, it is possible that the response rate was higher 
in PD patients with sleep disorders, thus the high frequency 
of RBD. On the other hand, previous studies have shown that 
RBD symptoms often remain undetected by history based tools. 
As noted in the introduction, we could polysomnographically 
confirm RBD in 10 PD patients with RBDSQ score ≥ 10; 5 out 
of 10 PD patients with RBDSQ score ≤ 2 had RWA on PSG and 
gross body jerks with no distinctive abnormal behavior, thus the 
frequency of RBD in PD may be even higher than suggested by 
our questionnaire-based findings.
CONCLUSION
Probable RBD in PD is associated with more advanced dis-
ease, as suggested by longer disease duration and higher im-
pairment of daily living. It is also linked to sleep fragmentation 
(with patients with probable RBD reporting significantly more 
nighttime awakenings) and to hallucinations. Hallucinations 
might be linked to emotional disinhibition and to activation of 
limbic structures. Both sleep fragmentation and limbic activa-
tion might facilitate the occurrence of RBD in PD.
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Table S1—RBDSQ: (adapted from Stiasny-Kolster et al., 200718)
N Question answer
1. I sometimes have very vivid dreams. yes/no
2. My dreams frequently have an aggressive or action-packed content. yes/no
3. The dream contents mostly match my nocturnal behaviour. yes/no
4. I know that my arms or legs move when I sleep. yes/no
5. It thereby happened that I (almost) hurt my bed partner or myself. yes/no
6. I have or had the following phenomena during my dreams:
6.1. speaking, shouting, swearing, laughing loudly yes/no
6.2. sudden limb movements, “fights” yes/no
6.3. gestures, complex movements, that are useless during sleep, e.g., to wave, to salute, to frighten mosquitoes, falls off the bed yes/no
6.4. things that fell down around the bed, e.g., bedside lamp, book, glasses yes/no
7. It happens that my movements awake me. yes/no
8. After awakening I mostly remember the content of my dreams well. yes/no
9. My sleep is frequently disturbed. yes/no
10. I have/had a disease of the nervous system (e.g., stroke, head trauma, parkinsonism, RLS, narcolepsy, depression, epilepsy, 
inflammatory disease of the brain), which?
yes/no
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